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events before randomization and was based upon a liberalized
version of the inclusion criteria of the CAPRIE (Clopidogrel
Versus Aspirin in Patients at Risk of Ischemic Events) trial (3). Of
course, any subgroup needs to be interpreted with caution before
the results are applied broadly and we went to great lengths in the
paper to interpret our findings very conservatively and with the
appropriate caveats. The subgroup as defined is one that represents
a population in which it is biologically plausible that there might
be benefit, and the findings are in keeping with and an extension
of several other clopidogrel trials, such as the CLARITY (Clopi-
dogrel as Adjunctive Reperfusion Therapy), COMMIT (Ran-
domized Placebo-Controlled Trial of Adding Clopidogrel to
Aspirin in 46,000 Acute Myocardial Infarction Patients), and
CURE (Clopidogrel in Unstable Angina to Prevent Recurrent
Events) studies (4–6). Importantly, we conclude by stating that
further study is necessary to validate our findings.
Dr. Gebel’s comparisons of our results to the CAPRIE trial, as
well as to the MATCH (Management of Atherothrombosis With
Clopidogrel in High-Risk Patients) trial, are flawed (7). In the
CHARISMA study, the comparison was clopidogrel to placebo,
with a background of aspirin therapy. In the CAPRIE trial, the
comparison was clopidogrel versus an active control, aspirin, with
no placebo arm. The MATCH trial was essentially a comparison
of aspirin versus placebo, with a background of clopidogrel. Thus,
interpretation of these trials and cross-comparison is not as simple
as Dr. Gebel portrays.
He concludes by stating that he does not think the findings
would be replicated if the trial were repeated. Indeed, one trial has
already been announced that will test the hypothesis of whether
adding a novel antithrombotic to aspirin is superior to aspirin alone
in patients with prior myocardial infarction, stroke, or peripheral
arterial disease. Likely, other trials will also test the value of
additional antithrombotic therapy in this patient population, such
that we will ultimately have further data to guide decision making
about optimal antithrombotic strategies for patients with prior
ischemic events.
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A Perspective on
Coronary Revascularization
in the PROactive 05 Study
Erdmann et al. (1) should be applauded for their recent contribu-
tion entitled “The Effect of Pioglitazone on Recurrent Myocardial
Infarction in 2,445 Patients With Type 2 Diabetes and Previous
Myocardial Infarction”. The PROactive 05 study is a post hoc
exploratory analysis of patients enrolled in the main PROactive
study that entered the study with a previous myocardial infarc-
tion (MI) (2). The investigators conclude that in high-risk
patients with type 2 diabetes and previous MI, pioglitazone
significantly reduced the occurrence of fatal and nonfatal MI
and acute coronary syndrome (1). These results provide criti-
cally important clinical data for pioglitazone, in light of Nissen
and Wolski’s (3) recent analysis suggesting increased risk of MI
with rosiglitazone use.
In the PROactive 05 study, cardiac intervention is defined as
coronary artery bypass graft (CABG) or percutaneous coronary
intervention (PCI) (1). Approximately 40% of the patients at
baseline had a previous PCI/CABG (1). In Table 5 under the
heading for individual end points, the investigators reported that
coronary revascularization (CABG and PCI) demonstrated a
nonsignificant absolute risk reduction (ARR) of 2% (1). This is
the most dynamic ARR among any of the individual end points.
This finding may be supported by the results of a recent
meta-analysis. That meta-analysis evaluated the effect of thia-
zolidinediones (TZDs) on reducing the risk of repeat target
vessel revascularization (TVR) after PCI (4). The results
suggested that TZDs, in fact, significantly reduce repeat TVR
after PCI (4). Although relative risk is reduced regardless of the
TZD used or the presence of diabetes, patients with diabetes
and studies evaluating pioglitazone seemed to show the most
robust benefit (4).
Because a large portion of patients at baseline had undergone
a previous coronary intervention, it would be interesting to
evaluate these patients separately to determine if this subgroup
would demonstrate a significant reduction in any coronary
revascularization. Additionally, it may be compelling to evaluate
pioglitazone’s effect on CABG and PCI separately. We suspect
that the majority of the absolute risk reduction for this end point
is driven by the PCI subset of patients. Such a finding could
substantiate the results reported in the meta-analysis by Riche et al.
(4) and may cast a new light on the darkening link between TZDs
and MI.
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Reply
We thank Drs. Riche and Dale for their letter commenting on the
PROactive 05 subanalysis in patients with myocardial infarction
(MI) at baseline. In that prespecified analysis, we reported that
pioglitazone reduced the occurrence of adverse cardiac outcomes,
including recurrent MI, in the 2,445 patients with previous MI (1).
Drs. Riche and Dale suggest that it would be useful to look
specifically at any reductions in cardiac revascularization in the
subgroup of patients who had had a previous cardiac intervention
(coronary artery bypass graft [CABG] or percutaneous interven-
tion [PCI]). We found that, in the full PROactive analysis set,
pioglitazone was equally effective in reducing the occurrence of first
revascularization relative to placebo in patients with a prior history
of cardiac intervention compared with those without such a history
(hazard ratio 0.88 in both patient groups; p for interaction between
subgroup and treatment  0.9960). Thus, in the total PROactive
population, there did not appear to be any extra benefit of pioglitazone
in the group with a prior history of coronary intervention.
Looking at the same end point in those with both a history of
MI and cardiac intervention at baseline, there was again no
evidence of a treatment subgroup interaction (hazard ratios 0.86 in
those with and 0.75 in those without prior PCI/CABG; p for
interaction between subgroup and treatment  0.6013). Only 140
patients had a prior CABG at baseline, but an analysis of those
with PCI (n  214) yielded a similar outcome.
One major limitation to these analyses is the high correlation
between the end points of MI/acute coronary syndrome (ACS)
and PCI/CABG. However, any direct effect on the risk of
PCI/CABG should be reflected in elective PCI/CABG rates.
Using the definition of elective PCI/CABG as occurring without
MI or ACS or occurring 30 days after MI/ACS, there were 123
events in the pioglitazone group and 132 in the placebo group
(hazard ratio 0.94; p  0.6135).
Taking all of the above information together, we conclude that,
in the PROactive study, pioglitazone reduced MI relative to
placebo and this was reflected in PCI/CABG rates, but there was
no conclusive evidence that pioglitazone influenced revasculariza-
tion rates differently.
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